Adrenocortical carcinoma – a review of current knowledge for Czech urological practice
Authors:
Marek Broul 1 3; Aneta Hujová 3; Michaela Liegertová 4; Lucie Radovnická 5
Authors‘ workplace:
Sexuologické oddělení, Krajská zdravotní, a. s. – Masarykova nemocnice v Ústí nad Labem, o. z
1; Urologické oddělení, Krajská zdravotní, a. s. – Nemocnice Litoměřice, o. z.
2; Fakulta zdravotnických studií UJEP v Ústí nad Labem
3; Přírodovědecká fakulta UJEP v Ústí nad Labem
4; Interní oddělení, Krajská zdravotní, a. s. – Masarykova nemocnice v Ústí nad Labem, o. z
5
Published in:
Ces Urol 2025; 29(2): 69-75
Category:
Review article
doi:
https://doi.org/10.48095/cccu2025012
Overview
Summary: Adrenocortical carcinoma (ACC) is a rare but highly aggressive malignancy of the adrenal cortex, accounting for less than 0.2% of all solid tumors. Despite its low incidence, ACC is associated with significant morbidity and mortality and requires a multidisciplinary diagnostic and therapeutic approach. This review summarizes current knowledge of the epidemiology, etiology, diagnostics, staging, treatment strategies, and follow-up of ACC, with an emphasis on the specifics of Czech clinical urological practice. Special attention is paid to the integration of hormonal diagnostics, imaging modalities (including advanced PET/MR and novel tracers), and genetic aspects relevant to ACC pathogenesis. Surgical resection remains the cornerstone of curative treatment, complemented by adjuvant therapy with mitotane and, in advanced cases, cytotoxic chemotherapy. Emerging therapeutic options, including immunotherapy and targeted agents, are also discussed. Given the rarity and complexity of ACC, centralization of care, adherence to international guidelines, and interprofessional collaboration are essential to improving patient outcomes in the Czech Republic.
Keywords:
adrenocortical carcinoma – adrenal gland – hormonally active tumor – mitotane – surgical treatment – chemotherapy – diagnostics – staging – urological practice – targeted therapy
Sources
- Else T, Kim AC, Sabolch A et al. Adrenocortical carcinoma. Endocr Rev 2014; 35(2): 282–326. doi: 10.1210/er.2013-1029.
- SVOD.CZ. Portál epidemiologie novotvarů v ČR [online]. Dostupné z: https://www.svod.cz/.
- Bajčiová V, Tomášek J, Štěrba J (eds). Nádory adolescentů a mladých dospělých. Praha: Grada Publishing, a.s. 2011.
- Fassnacht M, Kroiss M, Allolio B. Update in adrenocortical carcinoma. J Clin Endocrinol Metab 2013; 98(12): 4551–4564. doi: 10.1210/jc.2013-3020.
- Else T. Association of adrenocortical carcinoma with familial cancer susceptibility syndromes. Mol Cell Endocrinol 2012; 351(1): 66–70. doi: 10.1016/j.mce.2011.12.008.
- Lehmann T, Wrzesinski T. The molecular basis of adrenocortical cancer. Cancer Genet 2012; 205(4): 131–137. doi: 10.1016/j.cancergen.2012.02.009.
- Thampi A, Shah E, Elshimy G et al. Adrenocortical carcinoma: a literature review. Transl Cancer Res 2020, 9(2): 1253–1264. doi: 10.21037/tcr.2019.12.28.
- Yu K, Athimulam S, Saini J et al. Serum steroid profiling in the diagnosis of adrenocortical carcinoma: a prospective cohort study. J Clin Endocrinol Metab 2025; 110(4): 1177–1186. doi: 10.1210/clinem/dgae604.
- Silins I, Sundin A, Lubberink M et al. First-in-human evaluation of [18F]CETO: a novel tracer for adrenocortical tumours. Eur J Nucl Med Mol Imaging 2023; 50(2): 398–409. doi: 10.1007/s00259-022-05957-9.
- Libé R. Adrenocortical carcinoma (ACC): diagnosis, prognosis, and treatment. Front Cell Dev Biol 2015; 3: 45. doi: 10.3389/fcell.2015.00045.
- Chukkalore D, MacDougall K, Master V et al. Adrenocortical carcinomas: molecular pathogenesis, treatment options, and emerging immunotherapy and targeted therapy approaches. Oncologist 2024; 29(9): 738–746. doi: 10.1093/oncolo/oyae029.
- Crona J, Baudin E, Terzolo M et al. ENSAT registry-based randomized clinical trials for adrenocortical carcinoma. Eur J Endocrinol 2021; 184(2): R51– R59. doi: 10.1530/EJE-20-0800.
- Papotti Mauro, Libé R, Duregon E et al. The Weiss score and beyond – histopathology for adrenocortical carcinoma. Horm Canc 2011; 2: 333–340. doi: 10.1007/s12672-011-0088-0
- Sinclair TJ, Gillis A, Alobuia WM et al. Surgery for adrenocortical carcinoma: When and how? Best Pract Res Clin Endocrinol Metab 2020; 34(3): 101408. doi: 10.1016/j.beem.2020.101408.
- Puglisi S, Calabrese A, Basile V et al. New perspectives for mitotane treatment of adrenocortical carcinoma. Best Pract Res Clin Endocrinol Metab 2020; 34(3): 101415. doi: 10.1016/j.beem.2020.101415.
- Ardolino L, Hansen A, Ackland S et al. Advanced adrenocortical carcinoma (ACC): a review with focus on second-line therapies. Horm Cancer 2020; 11(3–4): 155–169. doi: 10.1007/s12672-020-00385-3.
- Sarrafan-Chaharsoughi Z, Yazdian Anari P, Malayeri AA et al. Update on adrenocortical carcinoma. Urol Clin North Am 2025; 52(2): 275–286. doi: 10.1016/j.ucl.2025.01.009.
- Hartmann I, Čtvrtlík F, Fryšák Z et al. Adrenokortikální karcinom. Urol Praxi 2016; 17(5): 206–209. doi: 10.36290/uro.2016.053
- Kuhn M, Domes L, Plintovič M et al. Adrenocortical carcinoma. Urol Praxi 2016; 17(1): 38–39. doi: 10.36290/uro.2016.011
- Broul M, Schraml J, Bočan M et al. Adrenokortikální karcinom – kazuistika. Ces Urol 2009; 13(4): 313.
- Broul M, Schraml J, Sticová E et al. Adrenokortikální karcinom. Urol Praxi 2010; 11(4): 200–203.
Labels
Paediatric urologist Nephrology UrologyArticle was published in
Czech Urology
Most read in this issue
- Minimally invasive ureterolysis in retroperitoneal fibrosis (Ormond´s disease) – video
- Adrenocortical carcinoma – a review of current knowledge for Czech urological practice
- Editorial
- Non-invasive urinary biomarkers in the diagnosis and monitoring of bladder cancer